- Home
- CRMD vs NPB Comparison
CRMD vs NPB Comparison
Compare CRMD & NPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- NPB
- Stock Information
- Founded
- CRMD 2006
- NPB 1999
- Country
- CRMD United States
- NPB United States
- Employees
- CRMD N/A
- NPB N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- NPB
- Sector
- CRMD Health Care
- NPB
- Exchange
- CRMD Nasdaq
- NPB NYSE
- Market Cap
- CRMD 464.7M
- NPB 421.7M
- IPO Year
- CRMD 2010
- NPB 2025
- Fundamental
- Price
- CRMD $11.63
- NPB $14.16
- Analyst Decision
- CRMD Strong Buy
- NPB Buy
- Analyst Count
- CRMD 6
- NPB 2
- Target Price
- CRMD $15.00
- NPB $17.25
- AVG Volume (30 Days)
- CRMD 2.3M
- NPB 130.2K
- Earning Date
- CRMD 05-06-2025
- NPB 01-01-0001
- Dividend Yield
- CRMD N/A
- NPB 0.18%
- EPS Growth
- CRMD N/A
- NPB 108.67
- EPS
- CRMD 0.28
- NPB 1.94
- Revenue
- CRMD $82,553,827.00
- NPB $191,534,000.00
- Revenue This Year
- CRMD $207.65
- NPB $23.72
- Revenue Next Year
- CRMD $50.13
- NPB $14.51
- P/E Ratio
- CRMD $41.90
- NPB $7.32
- Revenue Growth
- CRMD N/A
- NPB N/A
- 52 Week Low
- CRMD $3.61
- NPB $11.43
- 52 Week High
- CRMD $13.85
- NPB $14.98
- Technical
- Relative Strength Index (RSI)
- CRMD 69.76
- NPB N/A
- Support Level
- CRMD $11.21
- NPB N/A
- Resistance Level
- CRMD $12.31
- NPB N/A
- Average True Range (ATR)
- CRMD 0.67
- NPB 0.00
- MACD
- CRMD 0.32
- NPB 0.00
- Stochastic Oscillator
- CRMD 82.29
- NPB 0.00
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About NPB NORTHPOINTE BANCSHARES INC
Northpointe Bancshares Inc operates its business through its wholly-owned banking subsidiary, Its lending focus is the origination of residential mortgages throughout the United States. The majority of these loans are sold in the secondary market through a network of investors. The Company has also developed mortgage advance program that provides funding to pre-approved mortgage bankers who originate and sell individual conforming and non-qualified loan products in the secondary market. The Company continues to service loans that were originated and sold to investors as well as loans held in its portfolio which were originated and selectively held in portfolio.